Long-term real-world outcomes of nivolumab+ipilimumab treatment of unresectable pleural mesothelioma: update of Meso-Immune GFPC 04-2021 study.

Assié JB, Greillier L, Gobert A, Falchero L, Thibonnier L, Chasseray M, Raynaud C, Picchi H, Chatellier T, Corre R, Molinier O, Bakebe A, Naltet C, Quillot FM, Gavoille L, Pierret T, Dot JM, Wislez M, Sabatini M, Tiercin M, Zalcman G, Cassuto O, Largillier R, Madroszyk A, Munsch N, Pichon E, Ricordel C, Bylicki O, GFPC

Open source

DOI: 10.1016/j.lungcan.2026.109622
Published: 2026 Sep 8
Container: Lung cancer (Amsterdam, Netherlands)
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.lungcan.2026.109622,
  title = {Long-term real-world outcomes of nivolumab+ipilimumab treatment of unresectable pleural mesothelioma: update of Meso-Immune GFPC 04-2021 study.},
  author = {Assié JB and Greillier L and Gobert A and Falchero L and Thibonnier L and Chasseray M and Raynaud C and Picchi H and Chatellier T and Corre R and Molinier O and Bakebe A and Naltet C and Quillot FM and Gavoille L and Pierret T and Dot JM and Wislez M and Sabatini M and Tiercin M and Zalcman G and Cassuto O and Largillier R and Madroszyk A and Munsch N and Pichon E and Ricordel C and Bylicki O and GFPC},
  year = {2026},
  journal = {Lung cancer (Amsterdam, Netherlands)},
  doi = {10.1016/j.lungcan.2026.109622},
  url = {https://doi.org/10.1016/j.lungcan.2026.109622}
}

RIS

TY  - JOUR
TI  - Long-term real-world outcomes of nivolumab+ipilimumab treatment of unresectable pleural mesothelioma: update of Meso-Immune GFPC 04-2021 study.
AU  - Assié JB
AU  - Greillier L
AU  - Gobert A
AU  - Falchero L
AU  - Thibonnier L
AU  - Chasseray M
AU  - Raynaud C
AU  - Picchi H
AU  - Chatellier T
AU  - Corre R
AU  - Molinier O
AU  - Bakebe A
AU  - Naltet C
AU  - Quillot FM
AU  - Gavoille L
AU  - Pierret T
AU  - Dot JM
AU  - Wislez M
AU  - Sabatini M
AU  - Tiercin M
AU  - Zalcman G
AU  - Cassuto O
AU  - Largillier R
AU  - Madroszyk A
AU  - Munsch N
AU  - Pichon E
AU  - Ricordel C
AU  - Bylicki O
AU  - GFPC
PY  - 2026
JO  - Lung cancer (Amsterdam, Netherlands)
DO  - 10.1016/j.lungcan.2026.109622
UR  - https://doi.org/10.1016/j.lungcan.2026.109622
ER  -

APA

JB, A., L, G., A, G., L, F., L, T., M, C., C, R., H, P., T, C., R, C., O, M., A, B., C, N., FM, Q., L, G., T, P., JM, D., M, W., M, S., M, T., G, Z., O, C., R, L., A, M., N, M., E, P., C, R., O, B., & GFPC (2026). Long-term real-world outcomes of nivolumab+ipilimumab treatment of unresectable pleural mesothelioma: update of Meso-Immune GFPC 04-2021 study.. Lung cancer (Amsterdam, Netherlands). https://doi.org/10.1016/j.lungcan.2026.109622

Source records

pubmed · retrieved 2026-09-25T10:28:33.244Z